Preferred Label : Dostarlimab;

NCIt synonyms : Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer; Dostarlimab-gxly;

NCIt definition : A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.;

UNII : P0GVQ9A4S5;

CAS number : 2022215-59-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2022215-59-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Jemperli;

Molecule name : TSR-042; ANB011; TSR 042;

NCI Metathesaurus CUI : CL1676862;

Codes from synonyms : 34976;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/dostarlimab
2021
false
false
false
France
French
risk management
Dostarlimab
antibodies, monoclonal, humanized
infusions, intravenous
patient education handout
Drug-Related side effects and adverse reactions
signs and symptoms

---
https://www.has-sante.fr/jcms/p_3296883/fr/jemperli-500-mg-dostarlimab
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
Dostarlimab
adult
endometrial neoplasms
infusions, intravenous
antineoplastic agents
dostarlimab
microsatellite instability
Microsatellite instability-high solid malignant tumor (disorder)
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed
Mismatch Repair Deficiency
evaluation of the transparency committee

---
https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Dostarlimab
Dostarlimab
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
dostarlimab
antineoplastic agents
antineoplastic agents
endometrial neoplasms
endometrial neoplasms
infusions, intravenous
programmed cell death 1 receptor
drug monitoring
adult
aged
Mismatch Repair Deficiency
High-Frequency Microsatellite Instability
Advanced Uterine Corpus Cancer
Recurrent Uterine Corpus Cancer
Microsatellite instability-high solid malignant tumor (disorder)
Cancer Progression
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed

---
https://ansm.sante.fr/tableau-atu-rtu/dostarlimab-50-mg-ml-solution-pour-perfusion
2020
false
false
false
France
French
package leaflet
summary of product characteristics
guidelines for drug use
Dostarlimab
dostarlimab
infusions, intravenous
adult
endometrial neoplasms
antibodies, monoclonal
Antineoplastic Agents, Immunological
microsatellite instability
Mismatch Repair Deficiency
Microsatellite instability-high solid malignant tumor (disorder)

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.